A minimally Invasive surgical platform aGainst paNcreatIc and biliary Tract cancErs using cold atmospheric PLASMA

This project aims to develop a novel cold atmospheric pressure plasma system for minimally invasive treatment of pancreatic and biliary tract cancers, integrating advanced modeling and in-vivo testing.

Subsidie
€ 2.792.500
2024

Projectdetails

Introduction

Cancer is one of the major causes of death in Europe. Pancreatic (PC) and biliary tract (BTC) cancer are rare gastrointestinal adenocarcinomas with an increasing incidence, particularly among the elderly and women in an ageing European population. The poor prognosis of these cancers poses major clinical challenges and a significant public health burden.

Cold Atmospheric Pressure Plasma (CAP)

Cold atmospheric pressure plasma (CAP) has shown potential in regressing various cancer types in laboratory settings. Owing to its properties, CAP is a unique source of high concentrations of reactive radicals, electrons, ions, UV, etc., that may induce various effects in living tissue.

Selectivity of CAP

CAP has demonstrated selectivity in treating cancer cells with minimal effects on healthy ones. This selectivity renders plasma suitable for treating carcinomas in very sensitive areas or organs where there is an unmet need to minimize damage and side effects.

Delivery Mechanism

CAP can be delivered through dielectric tubes of variable length, making it ideal for minimally invasive and precise laparoscopic and endoscopic operations.

Current Market Gap

Despite the great promise and potential of this concept, there is currently no single laparoscopic or endoscopic medical platform in the market based on CAP to treat carcinomas.

Proposed Solution

This project proposes a novel solution using cutting-edge plasma technology, in-silico models, and a system-level approach.

Integration of Technologies

  1. Combine plasma with tumor multiscale simulations.
  2. Take input from pre-surgery diagnostics for in-silico model initialization.
  3. Determine the CAP operational window.

Demonstration and Future Steps

The developed technology will be demonstrated through in-vivo experiments. Additionally, the foundations for clinical trials and market introduction for CAP-based care of PC/BTCs will be laid out in this project.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.792.500
Totale projectbegroting€ 2.792.500

Tijdlijn

Startdatum1-4-2024
Einddatum31-3-2028
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • UNIVERSITY OF CYPRUSpenvoerder
  • SORBONNE UNIVERSITE
  • PANEPISTIMIO PATRON
  • OGKOLOGIKO KENTRO TRAPEZAS KYPROU
  • SYNNOUS LIMITED

Land(en)

CyprusFranceGreeceUnited Kingdom

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer

LASERBLOOD aims to develop a non-invasive blood test using fluorescence lifetime analysis of personalized protein corona to enable early detection of pancreatic cancer, potentially reducing mortality rates significantly.

€ 2.988.461
EIC Pathfinder

MULTIMODE NONLINEAR FIBER BASED ENDOSCOPIC IMAGING AND TREATMENT

MULTISCOPE aims to revolutionize optical diagnostics and therapy by developing a dual-function endoscopic device for real-time optical biopsy and cold atmospheric plasma treatment in gastrointestinal care.

€ 2.863.733
EIC Pathfinder

Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.

NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.

€ 5.972.875
EIC Pathfinder

Specific Conjugation of Antibodies to Lipid Photo-peroxidised cancer tissues for their immunogenic ELimination

SCALPEL aims to revolutionize cancer treatment by using photodynamic therapy to destroy tumors while marking surviving cells for immune system targeting, potentially offering a curative photoimmunotherapy.

€ 4.554.301
EIC Pathfinder

2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography Approach

PERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects.

€ 2.740.675

Vergelijkbare projecten uit andere regelingen

Mkb-innovati...

SupraTag

Een innovatieve hydrogel voor gecontroleerde medicijnafgifte bij peritoneale carcinomatose verbetert de behandeling en vermindert bijwerkingen.

€ 200.200
ERC Proof of...

Transforming bone cancer therapy with composite biomaterials encapsulating plasma-generated RONS

TRANSFORMER aims to develop a novel therapy combining cold atmospheric plasma-treated hydrogels with biomaterials for simultaneous osteosarcoma treatment and bone regeneration, enhancing patient outcomes.

€ 150.000
Mkb-innovati...

PRO CellecT

Pan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren.

€ 20.000
Mkb-innovati...

Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker

De ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren.

€ 20.000
ERC Proof of...

Targeting bicarbonate transport as a “first-in-class” therapeutic strategy to promote CD8+ T cell fitness and enhance cancer immunotherapy

This project aims to develop and commercialize bicarbonate transporter blockers to enhance CD8+ T cell efficacy and improve immunotherapy outcomes in pancreatic cancer.

€ 150.000